Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

NCT06930976 | Recruiting

• 1 other identifier: 241348
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Conditions

Glucose; Metabolism; Isotope Labeling; Immune System and Related Disorders

Outcome Measures

Primary Outcomes (1)

• 13C6-glucose uptake in immune cells

  Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.

  Up to 4 hours

Study Arms (1)

13C6-Glucose

OTHER

10-25gm of 13C6-Glucose

Drug: 13C6-Glucose

Interventions

13C6-Glucose DRUG

Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion

13C6-Glucose

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18 or older

You may not qualify if:

• Pregnant
• Prisoner or in police custody
• Uncontrolled hyperglycemia/diabetes
• Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
• Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
• Any reason which, in the opinion of the study investigator, adds additional risk to the participant

Sponsors & Collaborators

• Vanderbilt University Medical Center: lead

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

RECRUITING

Study Officials

• Matthew T Stier, M.D., Ph.D.

  Vanderbilt University Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Matthew T Stier, M.D., Ph.D.

CONTACT

615-875-4978; matthew.stier@vumc.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Medicine

Study Record Dates

• First Submitted: April 8, 2025
• First Posted: April 16, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: November 4, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
• Time Frame: The data will become available within 6 months of publication of the outcomes and will remain available for at least 5 years.
• Access Criteria: Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Principle Investigator and relevant institutional review boards.

Locations

US (1)